Статья: Пищевод Баррета

37. Yates M. et al. Dietary fat intake in the aetiology of Barrett's oesophagus and oesophageal adenocarcinoma-data from a prospective cohort study (EPIC-Norfolk) using 7-day food diary data //Gastroenterology. - 2011. - Т. 140. - №. 5. - С. S-80.

38. Leggett C. L. et al. Metabolic Syndrome as a Risk Factor for Barrett Esophagus: A Population-Based Case-Control Study //Mayo Clinic Proceedings. - Elsevier, 2013. - Т. 88. - №. 2. - С. 157-165.

39. Nelsen E. M. et al. Distribution of body fat and its influence on esophageal inflammation and dysplasia in patients with Barrett's esophagus //Clinical Gastroenterology and Hepatology. - 2012. - Т. 10. - №. 7. - С. 728-734.

40. Ogunwobi O. Leptin enchances the cell proliferative and anti-apoptotic actions of acid in Barrett's adenocarcinoma\\ 13 UEGW. - p. 6.

41. Kara M.A., Peters F.P., Rosmolen W.D. et al. High- resolution endoscopy plus chromoendoscopy or narrow-band imaging in Barrett's esophagus: a prospective randomized crossover study // Endoscopy. - 2005. - Vol. 37, N 10. - Р. 929-936.

42. Kuipers E.J., Haringsma J. Diagnostic and therapeutic endoscopy // J. Surg. Oncol. - 2005. - Vol. 92, N 3. - Р. 203-209.

43. Guda N.M., Partington S., Vakil N. Inter- and intra- observer variability in the measurement of length at endoscopy: Implications for the measurement of Barrett's esophagus // Gastrointest. Endosc. - 2004. - Vol. 59, N 6. - Р. 655-658.

44. Spechler S.J. Screening and surveillance of Barrett's esophagus // Gastroenterol. Hepatol. - 2005. - Vol. 1,N 2. - P. 91-93.

45. Armstrong D., Marshall J.K., Chiba N. Canadian Association of Gastroenterology GERD Consensus Group. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004 // Can. J. Gastroenterol. - 2005. - Vol. 19, N 1. - Р. 15-35.

46. El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE.Proton pump inhibitors are associated with reduced incidence of dysplasia inBarrett's esophagus. Am J Gastroenterol. 2004 Oct;99(10):1877-83.

47. Mardini HE. Preventing dysplasia in Barrett's esophagus: are proton pump inhibitors the answer? Am J Gastroenterol. 2005 Apr;100(4):978-9.

48. Abdalla S.I., Lao-Sirieix P., Novelli M.R. et al.Gastrin-induced cyclooxygenase-2 expression in Barrett's carcinogenesis // Clin. Cancer Res. - 2004. - Vol. 10. - Р. 4784- 4792.

49. Corey K.E., Schmitz S.M., Shaheen N.J. Does a surgical antireflux procedure decrease the incidence of esophageal adenocarcinoma in Barrett's esophagus? A meta-analysis // Am. J. Gastroenterol. - 2003. - Vol. 98, N 11. - Р. 2390-2394.

50. Spechler S.J., Lee E., Ahnen D. Long-term outcome ofmedical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial // JAMA. - 2001. - Vol. 285, N 18. - Р. 2331-2338.

51. Gross G. , Canto M. and Hixson J. et al. (1999) Management of Barrett's esophagus. A national study of practice patterns and their cost implications. Am J Gastroenterol 94:3440-3447

52. Falk G. , Ours T. and Richter J. (2000) Practice patterns for surveillance of Barrett's esophagus in the United States. Gastrointest Endosc 52:197-203

53. Sharma P. , Sampliner R.E. and Camargo E. (1997) Normalization of esophageal pH with high dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 92:582-585

54. Malesci A. , Savarino V. and Zenith P. et al. (1996) Partial regression of Barrett's esophagus by long term therapy with high dose omeprazole. Gastrointest Endosc 44:700-705

55. Peters F. , Ganesh S. and Kuipers E. et al. (1999) Endoscopic regression of Barrett's oesophagus during omeprazole treatment: A randomised double blind study. Gut 45:489-494

56. Salo J.A. , Nemlander A. and Farkkila M. et al. (1996) Treatment of Barrett's metaplasia by antireflux surgery and endoscopic laser ablation. Clinical experience in ten patients. Gastroenterology 108:A1243(abstract)

57. Sampliner R.E., Fennerty M.B. and Garewal H.S. (1996) Reversal of Barrett's esophagus with acid suppression and multipolar electrocoagulation: Preliminary results. Gastrointest Endosc 44:523-525

58. Overholt B.F. and Panjehpour M. (1996) Photodynamic therapy for Barrett's esophagus: Clinical update. Am J Gastroenterol 91:1719-1723

59. Schulz H. , Meihlke S. and Antos D. et al. (2000) Ablation of Barrett's epithelium by endoscopic argon plasma coagulation in combination with high dose omeprazole. Gastrointest Endosc 51:659-663

60. РГА. Диагностика и лечение гастроэзофагеальной рефлюксной болезни // Пособие для врачей. - Москва. - 2010 г.

61. Трухманов А.С. Гастроэзофагеальная рефлюксная болезнь: клинические варианты, прогноз, лечение: Автореф. д-ра мед.наук. - М., 2008. - 41 с.

62. Кайбышева В.О., Трухманов А.С., Ивашкин В.Т. Гастроэзофагеальная рефлюксная болезнь, резистентная к терапии ингибиторами протонной помпы // РЖГГК. - 2011. - Т. ХХI. - № 4. - С. 4-13.

63. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group. Eur J Gastroenterol Hepatol 1998;10:119-24.

64. Crawley JA, Schmitt CM. How satisfied are chronic heartburn sufferers with their prescription medications? Results of the Patient Unmet Needs Study. J Clin Outcomes Manag 2000;7:29-34.

65. Inadomi JM, McIntyre L, Bernard L, et al. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): a prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003;98:1940-4.

66. Буеверов О.А., Лапина Т.Л. Дуоденогастроэзофагеальный рефлюкс как причина рефлюкс-эзофагита // Фарматека - 2006. - №1. - С.22-27.

67. Pazzi P, et al. Bile reflux gastritis in patients without prior gastric surgery: therapeutic effects of ursodeoxycholic acid. Curr Ther Res 1989;45: 476-87.

68. Кайбышева В.О., Сторонова О.А., Трухманов А.С., Ивашкин В.Т. Возможности внутрипищеводной рН-импедансометрии в диагностике ГЭРБ //РЖГГК. - 2013. - Т.23. - № 2. - С. 4-16.

69. Kahrilas P, Shaheen N, Vaezi M. American Gastroenterological Association Institute Technical Review on the Management of Gastroesophageal Reflux Disease.Gastroenterology 2008;135:1392-1413.

70. Пирогов С.С. Эндоскопические методики в уточняющей диагностике и лечении больных с пищеводом Барретта : автореф. дис. канд. мед.наук : 14.00.14. - M, 2010.

71. Sharma P, Dent J, Armstrong D et al. The development and validation of an endoscopic grading system for Barrett's esophagus: the Prague C & M criteria. Gastroenterology 2006; 131: 1392-9.

72. Pascu O, Lencu M. Barrett's esophagus. Rom. J. Gastroenterol. 2004; 13: 219-22.

73. Lukanich Jeanne M. Section I: epidemiological review. Semin Thorac Cardiovasc Surg. 2003 Apr;15(2):158-166.

74. Solaymani-Dodaran M. et al. Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux //Gut. - 2004. - Т. 53. - №. 8. - С. 1070-1074.

75. Ronkainen J, Aro P, Storskrubb T, Johansson SE, Lind T, Bolling-Sternevald E, Vieth M, Stolte M, Talley NJ, Agrйus L. Prevalence of Barrett's esophagus in the general population: an endoscopic study. Gastroenterology. 2005 Dec;129(6):1825-31.

76. Conio M. et al. Risk factors for Barrett's esophagus: A case-control study //International journal of cancer. - 2002. - Т. 97. - №. 2. - С. 225-229.

77. Breyer HP, Silva De Barros SG, Maguilinik I, et al. Does methylene blue detect intestinal metaplasia in Barrett's esophagus? Gastrointest Endosc 2003;57:505-9.

78. Руководство по гастроэнтерологии под ред. Комарова Ф. И., Гребенева А.Л., Шептулина А.А.- М.: Медицина - 1995 - Т.1-3.

79. Jankowski JA, Wright NA, Meltzer SJ, Triadafilopoulos G, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.//Am J Pathology - 1999 - V.154 - №4 - P.965-973.

80. Beigi FI, Horton PF, Pope CE. Histological consequences of gastroesophageal reflux in man.//Gastroenterology - 1970 - V.58 - N.2 - P.163-174.

81. Clickman JN, Chen JJ, Wang HH, et al. Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett?s esophagus.//Am J Surg Pathol - 2001 - V.25 - P. 569-578.

82. Barrett's Esophagus. / Giuli R., Siewert J., Couturier D., et al. - Paris: John Libbey Eurotext - 2003 - V.1-2.

83. Overholt B., Lightdale C., Wang K., et al. International, multicenter, partally blinded, randomized study of the efficacy of photodynamic therapy (PDT) using porfimer sodium for the ablation of high grade dysplasia in Barrett's esophagus: result of 24-month follow-up.// Gastroenterology - 2003- V.124 .

84. Sampliner R. Endoscopic ablative therapy for Barrett's esophagus.// Gastrointest Endosc. - 2004 - V.59 - P. 66-69.

85. Каприн А.Д., Старинский В.В., Г.В. Петрова. Состояние онкологической помощи населению России в 2012 году -М.: ФГУ «МНИОИ им. П.А. Герцена Минздравсоцразвития России», 2014.- 260 с

86. Шептулин А.А. Современные возможности и перспективы лечения резистентных форм гастроэзофагеальной рефлюксной болезни. РЖГГК. - 2010. - Т.20. - №6. -С.81-85.

87. Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut 2009;58:295-309.

88. Mueller J, Werner M, Stolte M. Barrett's esophagus: histopathologic definitions and diagnostic criteria. World J Surg 2004;28:148-54.

89. Goldblum JR. The significance and etiology of intestinal metaplasia of the esophagogastric junction. Ann Diagn Pathol 2002;6:67-73.

90. Spechler SJ. Short and ultrashort Barrett's esophagus -- what does it mean. Semin Gastrointest Dis 1997;8:59-67.

91. Weston AP, Krmpotich PT, Cherian R, et al. Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus. Am J Gastroenterol 1997;92:407-13.

92. Chang Y, Liu B, Liu GS, et al. Short-segment Barrett's esophagus and cardia intestinal metaplasia: A comparative analysis. World J Gastroenterol 2010;16:6151-4.

93. Goldblum JR, Richter JE, Vaezi M, et al. Helicobacter pylori infection, not gastroesophageal reflux, is the major cause of inflammation and intestinal metaplasia of gastric cardiac mucosa. Am J Gastroenterol 2002;97:302-11.

94. Wijetunge S, Ma Y, DeMeester S, et al. Association of adenocarcinoma of the distal esophagus, “gastroesophageal junction,” and “gastric cardia” with gastric pathology. Am J Surg Pathol 2010;34:1521-7.

95. Chandrasoma P, Wickramasinghe K, Ma Y, et al. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? Dis Esophagus 2007;20:36-41.

96. Chandrasoma P, Wijetunge S, DeMeester S, et al. Columnar-lined esophagus without intestinal metaplasia has no proven risk of adenocarcinoma. Am J Surg Pathol 2012;36:1-7.

97. Cassie L. Booth, Kevin S. Thompson. Barrett's esophagus: A review of diagnostic criteria, clinical surveillance practices and new developments.J Gastrointest Oncol. 2012 September; 3(3): 232-242.

98. Theisen J, Nigro JJ, DeMeester TR, et al. Chronology of the Barrett's metaplasia-dysplasia-carcinoma sequence. Dis Esophagus 2004;17:67-70.

99. Cameron AJ, Carpenter HA. Barrett's esophagus, high- grade dysplasia, and early adenocarcinoma: a pathological study. Am J Gastroenterol 1997;92:586-91.

100. Reid BJ, Haggitt RC, Rubin CE, et al. Observer variation in the diagnosis of dysplasia in Barrett's esophagus. Hum Pathol 1988;19:166-78.

101. Zhu W, Appelman HD, Greenson JK, et al. A histologically defined subset of high-grade dysplasia in Barrett mucosa is predictive of associated carcinoma. Am J Clin Pathol 2009;132:94-100.

102. Зайратьянц О.В., Зайратьянц Г.О., Мовтаева П.Р. Проблемы современной гастроэнтерологии: пищевод Барретта. // Клиническая и экспериментальная морфология. - 2011. - №2. - С.9-11.

103. Зайратьянц О.В. Маев И.В. Смольянникова В.А., Мовтаева П.Р. Патологическая анатомия пищевода Барретта. // Архив патологии. - 2011. - №3. - С.21-22

104. Чистяков С.С, Пирогов С.С., Кувшинов Ю.П. Опухоли пищеварительного тракта: Учебное пособие // Издательство: МИА Классификация: Онкология ISBN: 5894818575, 2011

105. Superficial and early cancers of the esophagus.//Davydov М, Delektorskaya VV, Kuvshinov YP, Lisovsky M, Pirogov SS, Udagawa H, Ueno M, Wang G. Ann N Y Acad Sci. 2014 Sep;1325:159-69. doi: 10.1111/nyas.12527.

106. Пирогов С.С., Соколов В.В., Каприн А.Д. и др. Конфокальная лазерная эндомикроскопия.принцип и алгоритм выполнения при исследовании желудка // Экспериментальная и клиническая гастроэнтерология, №3, 2014 с. 10-16

107. Rьdiger Siewert J, Feith M, Werner M, Stein HJ. Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg. 2000 Sep;232(3):353-61.

108. Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of bothmajor histologic types of esophageal carcinomas in selected countries, 1973-1995.Int J Cancer. 2002 Jun 20;99(6):860-8. Erratum in: Int J Cancer 2002 Oct20;101(6):599.

109. Stuart A.C. McDonald, Trevor A. Graham, Danielle L. Lavery, Nicholas A. Wright, Marnix Jansen The Barrett's Gland in Phenotype Space& Cellular and Molecular Gastroenterology and Hepatology&

110. Stuart J. Spechler Rhonda F. Souza. Barrett's Esophagus. N Engl J Med 2014; 371:836-845

111. Fitzgerald RC, di Pietro M, Ragunath K, British Society of Gastroenterology. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014 Jan;63(1):7-42. doi: 10.1136/gutjnl-2013-305372.

112. Manner H, Neugebauer A, Scharpf M The tissue effect of argon-plasma coagulation with prior submucosal injection(Hybrid-APC) versus standard APC: A randomized ex-vivo study. United European Gastroenterol J. 2014 Oct;2(5):383-90

113. Hage M, Siersema PD, van Dekken H. 5-aminolevulinic acid photodynamic therapy versus argon plasma coagulation for ablation of Barrett's oesophagus: a randomised trial. Gut. 2004 Jun;53(6):785-90

114. Gray NA, Odze RD, Spechler SJ. Buried metaplasia after endoscopic ablation of Barrett's esophagus: a systematic review. Am J Gastroenterol. 2011Nov;106(11):1899-90

115. Weston AP. Can deep freezing join the endoscopic Barrett's mucosal ablationparty? Cautious optimism is warranted. Gastrointest Endosc. 2005Dec;62(6):849-52.

116. Frank G. Gress,Endoscopic Management of Barrett's Esophagus: Advances in Endoscopic Techniques. American Society for Gastrointestinal Endoscopy Vol. 16, No. 3 January 2009

117. Stein HJ, Feith M, von Rahden BH, Siewert JR. Approach to early Barrett's cancer. World J Surg. 2003 Sep;27(9):1040-6. Epub 2003 Aug 18.

118. Cancer Facts & Figures 2014 cancer.org

119. Prasad GA, Wu TT, Wigle DA, Buttar NS. Endoscopic and surgical treatment of mucosal (T1a)esophageal adenocarcinoma in Barrett's esophagus. Gastroenterology. 2009 Sep;137(3):815-23

120. Tantau M, Mosteanu O, Pop T, Tantau A, Mester G. Endoscopic therapy of Barrett's esophagus and esophageal adenocarcinoma. J Gastrointestin Liver Dis.2010 Jun;19(2):213-7. Review.

121. American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American Gastroenterological Association medical positionstatement on the management of Barrett's esophagus. Gastroenterology. 2011 Mar;140(3):1084-91.

122. Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, Trudgill N, British Society of Gastroenterology. British Society ofGastroenterology guidelines on the diagnosis and management of Barrett's oesophagus. Gut. 2014 Jan;63(1):7-42

123. Gatenby P, Soon Y. Barrett's oesophagus: Evidence from the current meta-analyses. World J Gastrointes Pathophysiol. 2014 Aug 15;5(3): 1788710.4291 /wjgp. v5.i3.178.

124. Bertani H, Frazzoni M, Dabizzi E, Pigт F, Losi L, Manno M, Manta R, Bassotti G. Improved detection of incident dysplasia by probe-based confocal laser endomicroscopy in a Barrett's esophagus surveillance program. Dig Dis Sci. 2013 Jan;58(1):188-93.